Cytos Biotechnology AG Report issue

For profit Phase 1 Phase 2
Founded: Schlieren Switzerland (1995)
Status: Acquired by Kuros Biosurgery AG (2016)

Organization Overview

First Clinical Trial
2003
NCT00369616
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cytos Biotechnology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Essential Hypertension (Phase 2)

Hypersensitivity (Phase 2)

Hypertension (Phase 2)

Melanoma (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 18
  • # of Trial APIs: 9